Modificare „Aeglea BioTherapeutics, Inc.”

Pagina dedicata companiei Aeglea BioTherapeutics, Inc. listata cu simbolul US.AGLE

==Descriere companie==
Aeglea BioTherapeutics, Inc. (www.aeglea.com) is a clinical-stage biotechnology company. The Company is focused on developing human enzyme therapeutics to benefit people with rare metabolic diseases. The Company’s product candidates include pegzilarginase and AGLE-177. The Company's lead product candidate, pegzilarginase, is a recombinant human arginase one that enzymatically degrades the amino acid arginine to lower arginine levels in patients with Arginase one Deficiency. Its engineered pegzilarginase with modifications that enhance the stability and arginine-degrading activity of the enzyme in human plasma. The Company is evaluating Pegzilarginase in a global pivotal Phase III PEACE (Pegzilarginase Effect on Arginase one Deficiency Clinical Endpoints) trial and in a Phase II open-label extension study for patients with Arginase One Deficiency. Its AGLE-177, is a novel PEGylated, or polyethylene glycol modified, human enzyme engineered to reduce Homocystinuria.

==Grafic actiuni companie==
<iframe key="tradeville" path="graficSimbol/US.AGLE" />

==Ultimele stiri despre Aeglea BioTherapeutics, Inc. (US.AGLE)==
<dynamicpagelist>
category=US.AGLE
count=10
order=descending
addfirstcategorydate=false
</dynamicpagelist>

[[Categorie:US.AGLE]][[Categorie:Stiri despre companii]]